What is it about?
This paper provides a simple and efficient means to site-specifically incorporate the synthetic lipid core peptide (LCP) adjuvant into recombinant protein antigens. We demonstrate the utility of this system using an engineered polytonic recombinant protein designed to prevent infection caused by common group A streptococcal (GAS; Streptococcus pyogenes) strains circulating in an Indigenous population of northern Australia.
Featured Image
Why is it important?
Many protein antigens have been identified in the literature, however potent immunostimulatory adjuvants are needed for the successful use of these antigens in commercial vaccines. The conjugation of adjuvants to antigens ensures that all vaccine components reach the same cell, improving vaccine potency. Our technology also ensures that we produce a commercially viable, molecularly-defined vaccine, rather than a mixture of compounds.
Perspectives
This is an example of our laboratories core technology platform, which allows the site-specific conjugation of various types of adjuvants onto recombinant protein antigens. This technology is applicable to vaccines targeting many different diseases, and ensures that we produce a defined vaccine. Enhancements to this system were published in http://dx.doi.org/10.1021/bc500108b
Dr Peter Michael Moyle
University of Queensland
Read the Original
This page is a summary of: An efficient, chemically-defined semisynthetic lipid-adjuvanted nanoparticulate vaccine development system, Nanomedicine Nanotechnology Biology and Medicine, October 2013, Elsevier,
DOI: 10.1016/j.nano.2013.01.009.
You can read the full text:
Contributors
The following have contributed to this page
